Anna Elisabetta Brunetti1, Sabina Delcuratolo2, Vito Lorusso3, Loredana Palermo3, Angelo Di Giorgio4, Salvatore Pisconti5, Nicola Silvestris3. 1. Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy brunetti.ae@gmail.com. 2. Scientific Direction, National Cancer Institute "Giovanni Paolo II", Bari, Italy. 3. Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy. 4. Department of Surgery, Sapienza University of Rome, Rome, Italy. 5. Medical Oncology Unit, S.G. Moscati Hospital, Taranto, Italy.
Abstract
BACKGROUND: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. CASE REPORT: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. RESULTS: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. CONCLUSION: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease. Copyright
BACKGROUND:Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. CASE REPORT: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. RESULTS: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. CONCLUSION: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease. Copyright
Authors: Vivek Subbiah; Salah-Eddine Lamhamedi-Cherradi; Branko Cuglievan; Brian A Menegaz; Pamela Camacho; Winston Huh; Vandhana Ramamoorthy; Pete M Anderson; Raphael E Pollock; Dina C Lev; Wei Qiao; Mary Frances McAleer; Robert S Benjamin; Shreyaskumar Patel; Cynthia E Herzog; Najat C Daw; Barry W Feig; Alexander J Lazar; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald Journal: Nat Rev Dis Primers Date: 2022-10-06 Impact factor: 65.038
Authors: C Honoré; V Atallah; O Mir; D Orbach; G Ferron; C LePéchoux; J B Delhorme; P Philippe-Chomette; S Sarnacki; S Msika; P Terrier; O Glehen; H Martelli; V Minard-Colin; F Bertucci; J Y Blay; S Bonvalot; D Elias; A LeCesne; P Sargos Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Monika Scheer; Christian Vokuhl; Bernd Blank; Erika Hallmen; Thekla von Kalle; Marc Münter; Rüdiger Wessalowski; Maite Hartwig; Monika Sparber-Sauer; Paul-Gerhardt Schlegel; Christof M Kramm; Udo Kontny; Bernd Spriewald; Thomas Kegel; Sebastian Bauer; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Kirsi Jahnukainen; Jörg Fuchs; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak Journal: Cancer Med Date: 2019-01-16 Impact factor: 4.452